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Summary A total of 72 sporadic colorectal adenomas in 56 patients were studied for the presence of point
mutations in codons 12 and 13 of the K-ras gene and for HLA-DR antigen expression related to
clinicopathological variables. Forty K-ras mutations in 39 adenomas were found (54%): 31 (77%) in codon 12
and nine (23%) in codon 13. There was a strong relationship between the incidence of K-ras mutations and
adenoma type, degree of dysplasia and sex. The highest frequency of K-ras mutations was seen in large
adenomas ofthe villous type with high-grade dysplasia. Fourteen out of 15 adenomas obtained from 14 women
above 65 years of age carried mutations. HLA-DR positivity was found in 38% of the adenomas, large
tumours and those with high-grade dysplasia having the strongest staining. Coexpression of K-ras mutations
and HLA-DR was found significantly more frequently in large and highly dysplastic adenomas, although two-
way analysis of variance showing size and grade of dysplasia to be the most important variable. None of the
adenomas with low-grade dysplasia showed both K-ras mutation and HLA-DR positivity (P=0.004). K-ras
mutation is recognised as an early event in colorectal carcinogenesis. The mutation might give rise to peptides
that may be presented on the tumour cell surface by class II molecules, and thereby induce immune responses
against neoplastic cells.
Keywords: K-ras; HLA-DR; large bowel adenoma; dysplasia; polymerase chain reaction-restriction fragment
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The adenoma-carcinoma sequence has for several years been
accepted as the main pathway for the development of most
neoplasias in colorectal carcinogenesis (Muto et al., 1975).
This is thought to be a multistep process involving genetic
instability (Nowell, 1976), clonal expansion (Nowell, 1976),
and acquisition of malignant phenotype (Vogelstein et al.,
1988). Several abnormal genes have been found, with
mutations within the ras gene family being among the first
to appear (Bos et al., 1987; Forrester et al., 1987). Mutations
of K-ras, located on the short arm of chromosome 12, are
frequent in colorectal neoplasms. In adenocarcinomas
mutations in codons 12 and 13 of K-ras have been identified
in 39-65% of tumours (Bos et al., 1987; Vogelstein et al.,
1988; Burmer and Loeb, 1989; Breivik et al., 1994), and 80-
90% of them are present in codon 12 (Bos et al., 1987;
Vogelstein et al., 1988; Breivik et al., 1994).
Vogelstein et al. (1988) found ras mutations in 47% of
carcinomas, in 58% of adenomas greater than 1 cm, and in
less than 10% of adenomas 1 cm or smaller, indicating that
ras gene mutation is a relatively early event in colorectal
carcinogenesis. Miyaki et al. (1990) demonstrated that ras
mutations are frequently detected in adenomas with severe
dysplasia.
Whereas K-ras mutations in familial adenomatous
polyposis (FAP) adenomas are found with an overall
frequency of about 18%, sporadic adenomas showed higher
values, but with considerable variation in frequency, ranging
from 15% to 75% (reviewed by McLellan et al., 1993).
Furthermore, evidence for very early involvement of ras
mutations in up to 70% of aberrant crypt foci of the colon
has been provided (Pretlow et al., 1993; Yamashita et al.,
1995).
The expression of HLA-antigens has been studied in a
relatively small series of lesions, both in sporadic and FAP
adenomas and carcinomas (Gutierrez et al., 1987, 1990;
Degener et al., 1988). Both reduction in class I HLA-antigens
and 'de novo' expression of class II antigens have been
described for colorectal neoplasias. The significance of class I
and II MHC expression in the immune recognition of human
tumours is a matter of dispute. Recently we demonstrated
better survival of patients with HLA-DR-positive large bowel
carcinomas than of those without (Norheim Andersen et al.,
1993). Others, however, have been unable to show such a
relationship (Ghosh et al., 1986; Moller et al., 1991).
The purpose of this investigation was to study K-ras gene
mutations in adenomas and up-regulation of HLA-DR on
epithelial cells along with the traditional markers for
increasing malignant potential, such as tumour size, type
and grade of dysplasia. We aimed at searching for a possible
link between the genetic event and expression of the class II
determinant. Such a link would be important as HLA-DR
expression is necessary for recognition of tumour cells by
CD4-positive cells.
Materials and methods
Patient material
To obtain a sample of large bowel adenomas that was
balanced according to size, histological type and grade of
epithelial dysplasia, we chose 72 sporadic adenomas from 56
patients out of 513 consecutively obtained polyps. The main
shortcoming was the small number of villous adenomas
under 2 cm in diameter (Rognum et al., 1982). In addition,
12 adenomas from four patients with FAP were analysed.
The adenomas were obtained from colonoscopic, rectoscopic
and transabdominal polypectomies, and from segmental
resections of the colon removed because of carcinoma,
during the years 1978-1989. There were 30 men and 26
women with sporadic adenomas, and their median age was 65
years (range 28-92). Fifteen hyperplastic polyps from nine
patients were included as controls. Clinicopathological
characteristics of the patients are shown in Table I.
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Table I Clinicopathological characteristics of the patients
Sporadic FAP Hyperplastic
Number of patients 56 4 9
Sex
Male 30 3 4
Female 26 1 5
Median age (years) 65 32 59
Range 28-92 20-46 36-77
Number of polyps 72 12 15
Histological type
Tubular 30 11
Tubulovillous 24 1
Villous 18 0
Grade of dysplasia
Low grade 34 6
High grade 38 6
Localization
Right colon 22 7 5
Left colona 24 3 8
Rectum 26 2 2
Size
<10mm 24 7 12
10-20mm 16 4 3
>20 mm 32 1 0
aDescending and sigmoid.
Histopathological diagnosis was based upon 1-6 sections
from each adenoma, 110 sections altogether. The tumours
were categorized according to size, histological type and
grade of dysplasia (Table II).
Epithelial dysplasia was graded as low grade and high
grade by histopathological criteria according to the WHO
classification, in which low grade includes mild and moderate
dysplasia, and high grade corresponds to the former severe
dysplasia (Jass and Sobin, 1989). Histopathological evalua-
tions were done by two independent observers (SNA and
TOR).
Tumour material
The mucosal specimens were placed in 0°C, isotonic
phosphate-buffered saline (PBS), pH 7.6, immediately after
resection. Within 1 h samples for immunohistochemistry were
excised and placed in 96% ethanol at 4°C and further
processed for paraffin embedding (Brandtzaeg, 1974). Serial
sections cut at 6 gM were dewaxed and subjected to
immunofluorescence staining at room temperature. One
section from each series was stained by a trichrome routine
method (HAS) containing haematoxylin, azofloxin and
saffron. The next sections from each paraffin block were
cut at 20 gM for analysis of K-ras mutations in codons 12
and 13. The blade of the microtome was changed and
thoroughly cleaned twice in xylol and once in ethanol after
each sample to avoid cross-contamination.
Investigations of K-ras mutations
Enriched PCR amplification K-ras mutations in codons 12
and 13 were identified by a sensitive technique (modified from
Kahn et al., 1991), which will be outlined in detail elsewhere
(J. Breivik et al. in preparation). Sections 20 gM-thick from
the ethanol-fixed, paraffin-embedded tissue blocks were used
directly as templates in the initial polymerase chain reaction
(PCR) amplification (PCR Al). The material was put into
500 Ml tubes with 50 gil of PCR amplification buffer (50 mM
potassium chloride, 10 mM Tris HCl, 1.5 mM magnesium
chloride), 25 /IM of each deoxynucleoside triphosphate,
0.28 jtg TaqStart Antibody (Clontech, Palo Alto, CA,
USA), 1.25 U of Taq DNA polymerase (Promega, Madi-
son, WI, USA) and 0.04 gM and 0.2 gM of the oligonucleo-
tide primers (Genosys Biotechnology, TX, USA) 5K1 and
3K1 respectively:
5K1: 5'-ACTGAATATAAACTTGTGGTCCATGGAGCT-3'
3K1: 5'-TTATCTGTATCAAAGAATGGTCCTGCACCA-3'
The 5Ki primer was designed (modified, mismatching bases
are underlined) to induce two restriction sites in the wild-type
(WT) amplification product (N =any base):
5'-CCANNNNNNTGG-3'
is recognised by endonuclease BstXI, and involves WT codon
12.
5'-CCANNNNNNNNNTGG-3'
is recognised by endonuclease XcmI, and involves WT codon
13.
The amplification was performed in a GeneAmp PCR
System 9600 (Perkin-Elmer, CT, USA). The reaction was run
for ten cycles consisting of 30 s denaturation at 94°C, 1 min
annealing at 50°C, and 2 min elongation at 72°C. After the
last cycle the tubes were kept at the elongation temperature
for 8 min.
An aliquot of 10 ,l of the amplification product was
incubated with either 10 U of BstXI or 2 U of XcmI.
Digestion was performed as recommended by the supplier of
the endonucleases (both New England Biolabs, MA, USA),
in a volume of 20 Ml.
An aliquot of 5,l of the digested amplification product
was used directly as a template in ten cycles of a second
amplification reaction identical to PCR Al, designated PCR
A2. A 5 Ml aliquot of this amplification product was digested
with the same endonuclease and under identical conditions as
previously described.
Once again 5 ,l of the digested amplification product was
used directly as a template in an amplification reaction (PCR
B). This time 5K1 was used in combination with 0.2 uM of a
nested and modified 3' primer, amplifying a segment of
152 bp:
3K2: 5'-GGATGGTCCTCCACCAGTAATATGGATATTA-3'
3K2 contains both the restriction sites included in WT
amplification products by 5K1. A total of 30-40 cycles were
performed depending on the yield of the amplification.
Reaction conditions were as described previously.
Table II Samples of sporadic adenomas subjected to K-ras mutation analysis and HLA-DR study
Size
Grade of < 10 mm 10-20 mm >20 mm Total number
Dysplasia T TV V T TV V T TV V T TV V
Low grade 15 1 1 3 5 1 4 2 2 22 8 4
(n = 34)
High grade 2 4 1 3 2 2 3 10 11 8 16 14
(n=38)
72 17 5 2 6 7 3 7 12 13 30 24 18
T, tubular; TV, tubulovillous; V, villous.K-ras and HLA-DR in large bowel adenomas
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RFLP analysis Mutated amplification products were identi-
fied by restriction fragment length polymorphism (RFLP)
analysis. An aliquot of 16 ul of the product of PCR B was
digested with the same endonuclease and under identical
conditions as in the two intermediate digestion steps. The
digested products were run on a 4% agarose gel containing
ethidium bromide, and analysed in UV light. Mutated
products were cut only at the control site contained in
3K2, and identified as a 133 bp band. WT products were also
cut at the 5' end, and yielded a band of 107 bp.
DNA sequencing
For all mutation-positive samples the product of PCR B was
sequenced in order to identify the exact base substitution.
Direct sequencing was done by a modified dideoxy chain
termination method (Sanger et al., 1977), using the Sequenase
PCR Product Sequencing Kit (United States Biochemical,
Cleveland, OH, USA), under conditions recommended by the
manufacturer. A nested sequencing primer was used:
3K3: 5'-TATTAAAACAAGATTTAC-3'
Controls
DNA from colon carcinoma cell line SW480 (Clontech, Palo
Alto, CA, USA) and HCT116 (American Type Culture
Collection, ATCC, Rockville, MD, USA) with known K-ras
mutations at codon 12 (GTT) and codon 13 (GAC)
respectively, were used as positive controls in each of the
parallel procedures. Negative controls, without DNA, were
run as controls of contamination. All mutation detection
experiments were confirmed using a second independent
amplification product.
HLA-DR immunohistochemistry
A murine monoclonal antibody to a non-polymorphic human
HLA-DR antigen, clone L234 (IgG2a, Beckton Dickinson,
Mountain View, CA, USA) was applied (1:20 for 20 h) in an
indirect three-step immunofluorescence method (Brandtzaeg
and Rognum, 1983), including affinity purified biotinylated
horse anti-mouse IgG (0.05 g IgGI-1, 3 h) and fluorescein
isothiocyanate (FITC)-labelled avidin (0.05 g 1-', 30 min),
both purchased from Vector Laboratories (Burlingame, CA,
USA).
Two or more samples were examined from most of the
larger adenomas. Thirty-nine of the sections showed varying
amounts of normal adjacent mucosa.
As a control colorectal biopsies from five normal persons
were included, as well as tissue from five resections owing to
colorectal carcinoma, taken at least 10 cm away from the
tumour.
Observations were done in a Leitz Aristoplan fluorescence
microscope equipped with an Osram Hg 100 W lamp for
fluorescein (green emission). Narrowband excitation and
selective filtration (Leica I3 513683) of the fluorescence
colour were obtained with a Ploem-type epi-illuminator.
Evaluation
The epithelial staining for HLA-DR antigens in adenomatous
mucosa was evaluated according to the percentage of positive
cells; 0, 1-5%, 5-25%, >25% respectively. Epithelial
staining in adjacent normal mucosa was also noticed. The
same investigator (SNA) was responsible for the fluorescence
scoring throughout the study. Reproducibility studies of a
similar fluorescence scoring system have been published
previously (Norheim Andersen et al., 1993).
Blind tests for intra- and interobserver reproducibility of
histological type and grade of epithelial dysplasia of the
adenomas were performed, and proportions of agreement (P)
and Kappa values were estimated in the analysis of observer
variability (Landis and Koch, 1977).
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Statistical analysis
The X2 test was used for statistical evaluation to relate the
size of polyps, type, degree of dysplasia, site and sex to K-ras
mutations and HLA-DR antigen expression. When the
numbers were small, Yates' correction was used. When
relating K-ras mutations, HLA-DR expression and classical
variables, two-way analysis of variance was used. P-values
less than 0.05 were regarded as statistically significant.
Results
Frequency of K-ras mutations
Forty mutations were found in 39 of 72 sporadic adenomas
(54%), 31 (77%) in codons 12 and 9 (23%) in codon 13. One
small adenoma (<1 cm) with high-grade dysplasia contained
both a codon 12 (Val) and a codon 13 (Asp) mutation. In
another small adenoma with high-grade dysplasia it was
technically impossible to amplify DNA for K-ras mutation
analysis.
The frequency of K-ras mutations tended to increase with
size (P=0.07), was significantly higher in adenomas with
high-grade dysplasia compared with low-grade (P=0.001),
and was related to type of adenomas with higher frequency in
villous/tubulovillous tumours than in tubular (P<0.001)
(Table III).
Location at the right side vs left side (descending, sigmoid
and rectum) of the large bowel did not show any significant
differences. Significantly more women than men showed K-
ras mutation (P= 0.001) (Figure 1). Among the 15 adenomas
from 14 older women only one adenoma, < 10 mm and with
low-grade dysplasia, did not show a point mutation. The
same patient, however, had a tubulovillous adenoma between
10 and 20 mm in diameter and with low-grade dysplasia,
containing a codon 12 GTT (Val) mutation.
The most frequent mutations were G-+A transitions (20/
40) and G-.T transversions (17/40). Only three G-+C
transversions were observed. Mutations in position 2 of a
codon occurred three times more frequently than in position
1 (75% vs 25%), (Figures 2 and 3).
Two patients had two separate adenomas containing a K-
ras mutation. One elderly woman 78 years of age showed
codon 12 G-+A transition (Asp) in one adenoma and G-+T
transversion (Val) in another. A man aged 61 years had a
codon 13 G-+A transition (Asp) in both adenomas.
Among the 12 adenomas from FAP patients only one
showed a K-ras mutation, found in codon 12 (Asp) in a
tubulovillous adenoma greater than 20 mm and with high-
grade dysplasia. This gives a mutation frequency of 8%,
which is significantly less frequent than in sporadic ones
(P<0.01).
None of the hyperplastic polyps showed any K-ras
mutation.
Table III K-ras mutation in sporadic adenomas according to
clinicopathological variables
Level of
K-ras+ (%) K-ras -(%) significance
Size (mm)
<10 11 (15) 13 (18)
10-20 6 (8) 10 (14) P=0.07
>20 22 (31) 10 (14)
Type
Tubular 8 (11) 22 (31)
Tubulovillous 15 (21) 9 (13) P<0.001
Villous 16 (22) 2 (3)
Dysplasia
Low grade 11 (15) 23 (32)
High grade 28 (39) 10 (14) P=0.001
I
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a
HLA-DR expression
Mononuclear cells in lamina propria were strongly positive
and served as internal controls in each section.
Thirty-nine of the 72 sporadic adenomas showed epithelial
staining for HLA-DR to a varying extent (54%) (Figure 4).
In 14 adenomas (19%) more than 25% of the neoplastic cells
were positive for HLA-DR, whereas 13 adenomas (18%)
C T A G
d
C T A G C T A G
*-G to C
4- GtoA
Figure 3 K-ras sequences from four adenomas showing
mutations. (a) 12 Val (GTT). (b) 12 Asp (GAT). (c) 12 Arg
(CGT). (d) 13 Asp (GAC). (G band in 3 B due to wild-type
sequence,).
Figure 1 Distribution of adenomas and mutations. 0, No
mutation; *, G-+A transition; 0, G-+T transversion; A, G-*C
transversion; *, mutations in both codons 12 and 13. Patients
were divided by sex and by whether younger or older than median
age (65 years). Percentage gives frequency of adenomas with
mutation in each group. Significantly more women than men had
K-ras mutations in their adenomas (P=0.001), and women above
65 years of age had significantly more K-ras than those below
(P<0.001).
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Figure 2 Frequency of the different base substitutions among
adenomas with mutation. The number of lesions is indicated
above the columns, and the base substitution and corresponding
amino acid are marked underneath.
Figure 4 Villous adenoma > 2cm with high-grade dysplasia. (a)
HAS staining (original magnification x 130). Detail of epithelium
with high-grade dysplasia to the right (original magnifica-
tion x 520). (b) Adjacent section stained green for HLA-DR
determinants (original magnification x 130).
b
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Table IV HLA-DR staining in sporadic adenomas according to clinicopathological variables
Area of HLA-DR positivity (%) Level of
Oa (%) 1-5 (%) 5-25 (%) >25 (%) significance
Size (mm)
< 10 17. (24) 2 (3) 4 (6) 1 (1)
10-20 8 (11) 3 (4) 4 (6) 1 (1) P=0.013
>20 8 (11) 7 (10) 5 (7) 12 (17)
Type
Tubular 15 (21) 7 (10) 4 (6) 4 (6)
Tubulovillous 9 (13) 4 (6) 5 (7) 6 (8) NS
Villous 9 (13) 1 (1) 4 (6) 4 (6)
Dysplasia
Low grade 23 (32) 4 (6) 3 (4) 4 (6)
High grade 10 (14) 8 (11) 10 (14) 10 (14) P=0.018
aThe groups with no staining and minimal staining (1-5%) were pooled.
a
Figure 5 Normal colorectal mucosa. (a) HAS staining (original
magnification x 130). (b) Adjacent section stained green for HLA-
DR determinants (original magnification x 130). Epithelium is
negative, whereas mononuclear cells in lamina propria show
positive staining.
showed HLA-DR staining in 5-25% of the cells. Scattered
staining in 1-5% of the cells was seen in 12 adenomas
(17%), and these were pooled with the totally negative
adenomas.
The expression of HLA-DR increased with size of polyps
(Table IV). Significantly more adenomas measuring 20 mm
or more were positive for HLA-DR, compared with smaller
polyps (P= 0.013). The expression of HLA-DR also increased
with grade of dysplasia (P=0.018). Among 34 adenomas
with low-grade dysplasia, 31% were definitely positive for
HLA-DR, whereas 74% of the 38 adenomas with high-grade
dysplasia showed positive staining in >5% of the epithelial
cells.
The staining was always heterogenous. Areas with high-
grade dysplasia often stained positive, but not invariably.
There was no relation between HLA-DR expression and
histological type of adenomas (Table IV, NS).
Figure 6 Hyperplastic polyp. (a) HAS staining (original
magnification x 130). (b) Adjacent section stained green for
HLA-DR determinants (original magnification x 130). Also here
epithelium is negative, while mononuclear cells in lamina propria
show positive staining.
Adenomas from the right side of the colon showed
significantly more HLA-DR positivity than left-sided ones
(P=0.003), whereas there were no statistically significant
differences in staining according to sex (P=0.25).
aK-ras and HLA-DR in large bowel adenomas
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In the 12 adenomas from FAP patients, only one (8%) -
with high-grade dysplasia and measuring between 10 and
20 mm - was strongly positive (>25%) for HLA-DR. The
rest showed either scattered staining in <5% of the cells or
no staining at all, which is not significantly different from
sporadic adenomas (P=0.12).
The ten sections with normal control mucosa and the 15
hyperplastic polyps investigated did not express HLA-DR
antigens in the epithelial cells, but mononuclear cells in
lamina propria were also strongly positive here (Figures 5
and 6).
Furthermore, sections from 39 of a total of 84 adenomas
included adjacent mucosa. Thirty-seven of these had
histologically normal mucosa, being without evidence of
epithelial HLA-DR expression. In the other two adenomas,
both above 2 cm, with high-grade dysplasia, and showing
strong HLA-DR staining, the epithelial cells in the adjacent
mucosa were weakly DR-positive. There were, however, more
inflammatory cells than normal in the lamina propria.
Interobserver reproducibility was 'substantial', both with
respect to grade of dysplasia (kappa=0.74) and histological
type (kappa =0.63) of the adenomas (Figure 7a-d).
Intraobserver reproducibility showed 'substantial' agreement
regarding histological type (kappa=0.73), and was 'almost
perfect' (kappa=0.83) when evaluating grade of dysplasia,
the second observations being performed blindly 12 weeks
after the first.
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K-ras mutations and HLA-DR expression
K-ras mutations were present in about half of the adenomas,
both the HLA-DR-positive and the HLA-DR-negative ones.
However, when dividing the adenomas into subgroups, the
picture became more complex. Among adenomas with high-
grade dysplasia and K-ras mutation, the majority also
expressed HLA-DR, whereas none of the low-grade
adenomas were both K-ras and HLA-DR positive
(P=0.004) (Figure 8). When using two-way analysis of
variance the relationship between K-ras and HLA-DR is
partly explained by size (P= 0.02, Figure 9, Table V) and
grade of dysplasia (P=0.03, Figure 8, Table V), but not by
type (P=0.55, Figure 10, Table V). Nevertheless, the
traditional markers of increasing malignant potential,
adenoma size and grade of dysplasia, are the most important
characteristics for both K-ras and HLA-DR separately.
Discussion
In the present study the polyps were tested using a new,
highly sensitive technique allowing detection of one mutated
K-ras codon 12 and 13 allele in the presence of 104- 105
copies of the wild-type allele. Since relatively few tumours are
reported to contain mutations in K-ras codon 61 or in N-ras,
these mutations were not examined.
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Figure 7 Scatter diagrams of interobserver and intraobserver reproducibility tests. The degree of accordance for histological grade
(a) between the first observer (SNA) and the second one (TOR) (P=0.87 (62/71), kappa=0.74) and (b) between two separate
observations by the same observer (SNA) (P=0.92 (77/84), kappa=0.83). The degree of accordance for histological type (c)
between the two observers (P=0.78 (55/71), kappa =0.63) and (d) between two separate observations by the same observer (SNA)
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Table V Two-way analysis of variance of K-ras mutation in
relation to HLA-DR and size, type and grade ofdysplasia
P-value
Models Factor Interaction
HLA-DR 0.85
Size 0.03 0.02
HLA-DI: 0.94
Type < 0.01 0.55
HLA-DR 0.26
Grade of dysplasia <0.01 0.03
High grade
20
15
10
5
Ras+ Ras+ Ras- Ras-
HLA-DR+ HLA-DR- HLA-DR+ HLA-DR-
Figure 8 Relationship between K-ras mutations and HLA-DR
distribution according to grade ofdysplasia. Number of lesions is
indicated above the columns. None of the low-grade dysplastic
adenomas showed both K-ras mutation and HLA-DR staining
(P=0.004).
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Figure 10 Relationship between K-ras mutations and HLA-DR
distribution according to type. Number of lesions is indicated
above the columns. None of the low-grade dysplastic adenomas
showed both K-ras mutation and HLA-DR staining (P=0.004).
incidence is lower, from 7% to 30% (Farr et al., 1988;
Miyaki et al., 1990; Sasaki et al., 1990; Ando et al., 1991,
1992). This suggests that FAP adenomas follow another
pathway in their tumorigenesis.
As in other investigations, most of the mutations were
found in codon 12 (78%). Corresponding to studies from the
USA, we detected mutations encoding aspartic acid and
valine (17 and 12 tumours respectively) being most common.
In contrast McLellan et al. (1993) found replacement of
glycine by valine and arginine to be most frequent in British
adenoma patients.
In an investigation of 251 colorectal carcinomas in a
Norwegian population, Breivik et al. (1994) found G-+A
transitions in 57% and G-.T transversions in 34%. This is in
agreement with the figures in the present study. In both
samples mutations in position 2 occurred three times more
frequently than in position 1, with figures being identical
(76% vs 24%). This might reflect the mutation profile in this
ethnic population. Breivik et al. (1994) detected K-ras codon
12 and codon 13 mutations in 39% of the carcinomas with a
method based on PCR amplification, blotting onto nylon
5
Ras+ Ras+ Ras- Ras-
HLA-DR+ HLA-DR- HLA-DR+ HLA-DR-
Figure 9 Relationship between K-ras mutations and HLA-DR
distribution according to size. Number of lesions is indicated
above the columns.
We showed that 39 of the 72 sporadic adenomas contained
a K-ras mutation. Only one of the 12 FAP adenomas was
positive (8%). This is in general agreement with previous
studies from the USA, reporting an incidence of 50
(Vogelstein et al., 1988) to 75% (Burmer and Loeb, 1989)
K-ras mutations in sporadic adenomas. In FAP patients the
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membranes and sequence-specific oligonucleotide hybridisa-
tion. These carcinomas are now being reinvestigated, using
this new technique (in preparation).
Most previous studies conclude that no K-ras mutations
are found in normal mucosa (Forrester et al., 1987; Soh et
al., 1993) except one in which two cases of codon 12 point
mutations in normal mucosa immediately adjacent to
carcinomas were found (Burmer and Loeb, 1989). In all
reports the frequency of K-ras mutations is lower in
colorectal carcinomas than in adenomas, but the figures
vary somewhat with the sensitivity of the methods used.
We found that the frequency of K-ras mutations tended to
increase with increasing size (P=0.07), and were significantly
more often found in high-grade epithelial dysplasia compared
with low grade (Table III). Vogelstein et al. (1988) reported
that the frequency of K-ras mutations was related to size, and
Scott et al. (1993) found more codon 12 mutations with
increasing size and grade of dysplasia. Furthermore, we
confirmed that tubulovillous and villous adenomas had
significantly higher mutation frequencies than tubular
adenomas (Vogelstein et al., 1988). These observations are
in contrast to McLellan et al. (1993), who did not find any
correlation with size or with any other variables, except for a
personal history of colorectal cancer. In the present study
four patients with sporadic adenomas had a synchronous
adenocarcinoma, but only one of them had a K-ras mutation
in an adenoma. Two of the FAP patients had a synchronous
carcinoma, but no K-ras mutation in the five adenomas
investigated. Our sample is, however, too small to elucidate
the question further.
One of the most surprising findings was the relation
between K-ras mutation and sex. All female patients above
65 years of age showed adenomas with mutation, as
compared with very few mutations among elderly men
(24%). Breivik et al. (1994) found a strikingly low frequency
of K-ras mutations in colonic carcinomas in younger male
patients compared with elderly women (more than 70 years).
Perhaps the high frequency of mutation in females might be
related to sex differences in faecal composition, bowel transit
time and bile components.
Distinct expression of HLA-DR was present in 38% of the
adenomas and increased with size and grade of epithelial
dysplasia, but was not related to histological type. However,
the amount of villous components is often a consequence of
the size of the adenoma. Previous studies (Gutierrez et al.,
1987, 1990; and Horie et al., 1990) have shown a correlation
between HLA-DR expression and grade of dysplasia,. the
former study also reporting higher HLA-DR expression in
villous than in tubular adenomas.
Although some groups claim to find expression of HLA-
DR in normal colorectal epithelium in humans (McDougall
et al., 1990; Tsioulias et al., 1992; Mayer and Shlien, 1987),
most investigations do not (Daar et al., 1982, 1984; Ghosh et
al., 1986; Momburg et al., 1986; Gutierrez et al., 1987;
Degener et al., 1988; Ruiz-Cabello et al., 1988; Norazmi et
al., 1989; Bedossa et al., 1990; Horie et al., 1990). The
discrepancy may be explained by the selection of normal
controls, as slight inflammatory changes are known to induce
DR-expression (Rognum et al., 1987). Another possibility
may be different technical procedures (Mayer and Shlien,
1987), or binding of avidin to mucus in goblet cells.
In pathological conditions, such as inflammation, dyspla-
sia and carcinoma, the epithelium may express varying
amounts of these antigens (Rognum et al., 1983, 1987;
Ruiz-Cabello et al., 1988). The presence of HLA-DR on the
surface membrane of the neoplastic cells is a prerequisite for
recognition by activated CD4+ T cells, and it has been
shown that the growth of colorectal cancer cells expressing
class II following y-interferon treatment is inhibited by
activated CD4+ T-helper cells (Gedde-Dahl III et al.,
1994), indicating a direct cytotoxic effect (Gjertsen et al.,
personal communication). The activation of such T cells
requires the presence of accessory molecules not usually
present on tumour cells. It is therefore believed that specific T
cells will be activated primarily by dendritic cells present in
the tumour or in the draining lymph nodes. Such T cells will
home to the tumour where release of cytokines, such as
tumour necrosis factor-a and y-interferon, may induce class II
molecules in the tumour.
The hyperplastic polyps showed neither HLA-DR expres-
sion nor K-ras mutation. In agreement with the present
study, Bedossa et al. (1990) found no expression of HLA-DR
in the epithelium of 15 hyperplastic polyps, in contrast to 8 of
15 adenomas, which showed patchy positivity. Jen et al.
(1994), however, found K-ras mutations in 5 of 22
hyperplastic polyps with diameter less than 10 mm. Our
observation gives support to the view that hyperplastic polyps
might be regarded as harmless lesions.
The coexpression of K-ras and HLA-DR in adenomas that
have the most malignant potential, i.e. the largest and those
with high-grade dysplasia, may be of interest, although the
two-way analysis of variance shows that size and grade of
dysplasia are of greatest importance for both K-ras mutation
and HLA-DR positivity, separately. The dissociation ofHLA-
DR positivity and K-ras mutation in right-sided adenomas
adds to the complexity of the relationship between the
markers. Nevertheless, co-expression of K-ras and DR might
be interpreted as a marker of carcinomatous development.
Previous studies (Jung and Schluesener, 1991; Gedde-Dahl
III et al., 1992a,b, 1993; Fossum et al., 1994) have
demonstrated that a variety of different HLA class II
molecules can bind and present ras peptides to T cells.
Fossum et al. (1994) described a specific immune response
against a synthetic peptide carrying the 13Asp mutation in
p21 ras in patient with colonic carcinoma, and the responding
T cells cloned from the peripheral blood of the patient were
of both CD4 and CD8 phenotype. The corresponding
mutation was not detected in the cancer, and the authors
therefore speculated that a specific T cell response resulted in
eradication of the tumour cells harbouring the 13Gly-+Asp
mutation. It was observed that the DQ7 molecule, which was
able to present the 13Gly-+Asp mutation, seemed to have a
modulating effect on the cancers carrying this mutation,
resulting in fewer tumours reaching advanced Dukes' stages
when DQ7 was present.
In our study none of the adenomas with low-grade
dysplasia showed both K-ras mutation and HLA-DR
positivity. This may perhaps indicate that adenomas at this
stage carrying both a ras mutation and expressing HLA-DR
are immunogenic, and therefore may be eliminated by the
immune system.
The majority of the K-ras-positive high-grade and large
adenomas also expressed HLA-DR. Several authors (Vogel-
stein et al., 1988; Ando et al., 1991) have reported a higher
incidence of ras mutations in large, colorectal adenomas as
compared with carcinomas. This indicates that some ras-
positive adenomas may either not develop into carcinomas
or, alternatively, will lose the expression of mutant ras
following some form of selective pressure.
It is tempting to speculate that in some of the adenomas,
the DR expression may reflect an ongoing immune response
directed at a tumour-specific antigen, such as mutated ras.
This immune response may eventually lead to a selective
elimination of cells expressing mutant ras. This scenario will
offer an explanation for the fact that K-ras mutations are less
frequent in carcinomas than in adenomas. Furthermore, this
view would be compatible with the observation that class II
expression is associated with a better prognosis in colorectal
carcinomas (Norheim Andersen et al., 1993).
It is known that colorectal cancers expressing multiple
mutations owing to DNA mismatch correction defects might
be highly immunogenic, often showing dense lymphocytic
infiltration (Kim et al., 1994). It has been speculated that this
may explain the more favourable prognosis observed within
this group of patients (Bodmer et al., 1994). In future studies
we plan to relate infiltration of T lymphocytes and their
subsets to K-ras and HLA-DR expression in both adenomas
and carcinomas.K-ras and HLA-OR in logo h d -do-aim
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